Pharmaceuticals
Feeling Queasy Over Moderna's Outlook? Investors May Still Get Their Shot
With an expected dip for 2023, the pharmaceutical company could see its mRNA technology win big over the long term -- and investors could be rewarded.
Let's See If Vertex Pharmaceuticals Can Push Higher on the Charts
Here's what traders should do.
Here's How to Treat Bristol-Myers Squibb's Charts
BMY is breaking out to a new high.
AbbVie Rallies After Its Test of the Rising 200-Day Moving Average Line
Let's review the charts and indicators.
Treat Becton, Dickinson and Company With Care
BDX gets an upgrade, but are the charts healthy enough to recommend?
When Times Are Tough, These 3 Mega-Caps Should Deliver the Dividends
Here's why in recessions and bear markets, the right mega-cap stocks can offer security -- and good yields.
Has Abbott Labs Declined to an Attractive Level?
Let's review the charts and indicators to see.
With Mergers Picking Up in the Beaten-Up Biotech Sector, Here's a Target I Like
This particular biotech company just saw its stock whacked but still holds a lot of promise.
Johnson & Johnson Appears to Be Running Out of Steam
The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.
I'm Keying in on ARKK Stocks to See if the Markets Are Ready to Bounce
Stabilization in the holdings of Cathie Wood's ARK Innovation ETF would be a positive in this trader's view.